Breaking News Instant updates and real-time market news.

IMAX

Imax

$20.00

0.42 (2.15%)

10:44
11/14/18
11/14
10:44
11/14/18
10:44

Imax management to meet with Wedbush

Meeting to be held in New York on November 14 hosted by Wedbush.

  • 14

    Nov

  • 14

    Nov

  • 04

    Dec

IMAX Imax
$20.00

0.42 (2.15%)

04/27/18
04/27/18
UPGRADE
Target $28

Buy
Imax upgraded to Buy on strong box office expectations at Benchmark
As previously reported, Benchmark analyst Mike Hickey upgraded Imax to Buy from Hold, saying he expects near-term performance to benefit from a strong box office with potential upside versus the consensus led by ongoing cost controls. He also suspects the company could raise its installation guidance for the year, as they did during the same period last year. Hickey set a $28 price target on Imax shares.
07/31/18
RILY
07/31/18
NO CHANGE
Target $26
RILY
Buy
B. Riley FBR adds Xperi to Alpha Generator list, removes Imax
B. Riley FBR analyst Eric Wold added Xperi (XPER) to his firm's Alpha Generator list in place of Imax (IMAX). The analyst sees an attractive entry point with Xper shares down 65% over past 18 months. Potential for multiple positive intellectual property licensing catalysts in next 6-12 months should lessen investor concerns, Wold tells investors in a research note. He has a Buy rating on Xperi with a $26 price target.
10/10/18
RILY
10/10/18
NO CHANGE
Target $34
RILY
Buy
Imax shares to move higher as two concerns dissipate, says B. Riley FBR
B. Riley FBR analyst Eric Wold believes Imax shares will benefit from the positive elimination of two major investor concerns, namely a lack of margin growth and China box office declines. He sees China per screens returning to growth just ahead of an "extremely" Imax- and China-friendly film slate in 2019. Further, without any new initiative margin headwinds, the company should return to 40%-plus EBITDA margins in 2019 for first time since 2010, Wold tells investors in a research note. He keeps a Buy rating on Imax with a $34 price target.
10/29/18
BRRR
10/29/18
NO CHANGE
Target $27
BRRR
Outperform
Imax price target lowered to $27 from $30 at Barrington
Barrington analyst James Goss lowered his price target for Imax to $27 following last week's Q3 results while keeping an Outperform rating on the shares. The analyst says that while Imax is seeing improving momentum, the company faces challenging box office comps in Q4.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.